CN103356932A - A pharmaceutical composition for treating vulvar squamous epithelial cell hyperplasia - Google Patents
A pharmaceutical composition for treating vulvar squamous epithelial cell hyperplasia Download PDFInfo
- Publication number
- CN103356932A CN103356932A CN2013102706363A CN201310270636A CN103356932A CN 103356932 A CN103356932 A CN 103356932A CN 2013102706363 A CN2013102706363 A CN 2013102706363A CN 201310270636 A CN201310270636 A CN 201310270636A CN 103356932 A CN103356932 A CN 103356932A
- Authority
- CN
- China
- Prior art keywords
- parts
- brown
- parched
- epithelial cell
- cell hyperplasia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a pharmaceutical composition for treating vulva squamous epithelial cell hyperplasia and a preparation method thereof, which aim to solve the problem of treatment of vulva squamous epithelial cell hyperplasia. The traditional Chinese medicine is characterized by being prepared from the following raw material medicines: cortex erythrinae, herba crotalariae albidae, cortex aristolochiae chinensis, magnolia sieboldii, parasitic loranthus, apios fortunei, charred malt, charred medicated leaven, Chinese ephedra root, Chinese littleleaf spurge, peach gum and cassia twig. Clinical experiments prove that the medicine for treating vulva squamous epithelial cell hyperplasia has the characteristics of good curative effect and higher safety, and is worthy of clinical application and popularization.
Description
Technical field
The present invention relates to the field of Chinese medicines, be specifically related to a kind of pharmaceutical composition for the treatment of the pudendum squamous hyperplasia.
Background technology
Squamous hyperplasia is take pruritus vulvae as cardinal symptom but agnogenic vulva, is referred to as the hypertrophy malnutrition in the past.In addition, any agnogenic pruritus vulvae after grabbing for a long time and rubbing, also can cause squamous hyperplasia.Be more common in 50 years old middle-aged women in the past, also can occur in the geratic period.Cardinal symptom is pruritus, and is how violent, is difficult to tolerance.Cause skin injury owing to repeatedly scratch and be on the rise, pruritus is more acute.The disease damage scope differs, and mainly involves labium majus, nympholabial furrow, and prepuce of clitoris such as unites at the place behind the labia, often be symmetry.When early lesion was lighter, skin color was dim red or greyish white, and the hyperkeratosis position then presents white.Owing to scratch for a long time and rub, pachyderma is like leather, and pigment increases, and it is obviously outstanding that skin texture becomes, and the cutaneous ridge protuberance is the flat pimple of most little polygonal property, and troops in flakes, lichenification occurs.Severe patient can cause because scratching epidermis breakage, crack, ulcer.
And the suppository of Chinese traditional treatment pruritus vulvae, outer lotion are many, but be mostly for Women of Childbearing Age, contain Radix Sophorae Flavescentis, Fructus Cnidii, the Fructus Kochiae, Rhizoma Smilacis Glabrae etc. in the prescription except the medicine of noxious dampness more, and mainly being the mucosa attenuation, the cause of pudendum squamous hyperplasia causes, the medicine external of above dispelling the damp pathogen with drugs of bitter in taste and cold in nature, then irritates nucous membrane more causes aggravation.
Summary of the invention
Technical assignment of the present invention is for above the deficiencies in the prior art, provides a kind of curative effect certainly and the pharmaceutical composition of the treatment pudendum squamous hyperplasia that side effect is little.
The technical scheme that the present invention solves its technical problem is: a kind of pharmaceutical composition for the treatment of the pudendum squamous hyperplasia is characterized in that being prepared from by the crude drug of following weight proportion: 10 ~ 30 parts of Cortex erythrinaes, 6 ~ 12 parts of Herba Crotalariae Ferrugineaes, go back 3 ~ 10 parts in bobbin, 6 ~ 12 parts of Flos Magnoliae Amoenae, 6 ~ 12 parts of 3 ~ 10 parts of, Radix Apioris Fortunei of Herba Taxilli, 6 ~ 12 parts of Fructus Hordei Germinatus (parched to brown)s, 6 ~ 12 parts of Massa Medicata Fermentata (parched to brown), 6 ~ 12 parts of Radix Ephedraes, 1 ~ 5 part of Folium Dalbergiae Mimosoidis, 3 ~ 10 parts of gumshiraz, 10 ~ 25 parts of Ramulus Cinnamomi.
Chinese medicine of the present invention is that the raw material by following optimum weight part proportioning is prepared from: 20 parts of Cortex erythrinaes, 10 parts of Herba Crotalariae Ferrugineaes, go back 6 parts in bobbin, 10 parts of Flos Magnoliae Amoenae, 10 parts of 6 parts of, Radix Apioris Fortunei of Herba Taxilli, 10 parts of Fructus Hordei Germinatus (parched to brown)s, 10 parts of Massa Medicata Fermentata (parched to brown), 10 parts of Radix Ephedraes, 2 parts of Folium Dalbergiae Mimosoidiss, 6 parts of gumshiraz, 20 parts of Ramulus Cinnamomi.
Wherein said: Cortex erythrinae is bark or the root bark of pulse family Erythrinae Arborescentis Erythrina indica Lam..Nature and flavor are bitter, and are flat.Return liver, kidney channel.But the merit wind-damp dispelling, channels sootheing and network vessel quickening.Wind-damp dispelling, the meridian dredging, parasite killing.
Herba Crotalariae Ferrugineae is leguminous plant falsely herb or the whole herb with root of blue rotalaria ferruginea Grah..The bitter little acid of nature and flavor; Flat cold.Return lung meridian.But the merit nourishing the kidney and liver, relieving cough and asthma, eliminating damp, detoxifying.
Also bobbin is the fruit of orchid Rhizoma Gastrodiae Gastrodia elata Bl..Sweet in the mouth; Cold in nature.But merit tonify deficiency subduing the wind syndrome.Main dizzy; Pupil; The wind syndrome of head headache; The weak breath consumption of essence; Early whitening of beard and hair.
Flos Magnoliae Amoenae for Magnoliaceae head Drymotaenium miyoshianum (Mak.) Mak. Magnolia amoena Cheng, is used as medicine with alabastrum.Nature and flavor are bitter, and are cold.But the merit diuresis, detumescence, nourishing the lung to arrest cough.
Herba Taxilli is the dry stem and branch with leaf of Loranthaceae plant Herba Taxilli Taxillus chinensis (DC.) Danser for Herba Taxilli.Nature and flavor are bitter, sweet, and are flat.Return liver, kidney channel.But the merit invigorating the liver and kidney, bone and muscle strengthening, wind-damp dispelling, antiabortive unit.
Radix Apioris Fortunei for pulse family Radix Apioris Fortunei platymiscium Radix Apioris Fortunei Apios fortunei Maxim., is used as medicine with tuber, leaf and seed.Sweet, the little hardship of nature and flavor, flat.But the merit heat-clearing and toxic substances removing, preventing phlegm from forming and stopping coughing.
Fructus Hordei Germinatus (parched to brown), for the mature fruit of grass Fructus Hordei Vulgaris Hordeum vulgare L. through the drying of germinateing, fry to burnt brown according to the method for frying, cool sieve dedust bits.Nature and flavor are sweet, and are flat.Return spleen, stomach warp.But the merit promote qi circulation digestion promoting, spleen benefiting and stimulating the appetite moves back newborn relieving distension.
Massa Medicata Fermentata (parched to brown), for the medicines such as Herba polygoni hydropiperis, Herba Artemisiae Annuae, Semen Armeniacae Amarum add flour or wheat bran mixed after, through the herbal leaven that fermentation forms, fry to burnt brown according to frying method.The sweet suffering of nature and flavor, temperature.Enter spleen, stomach warp.But the merit invigorating the spleen and regulating the stomach is in the accent that helps digestion.
Radix Ephedrae is the dry root and rhizome of Ephedraceae plant plait Herba Ephedrae Ephedra sinica Stapf or epheday intermedia Ephedra intermedia Schrenk et C. A. Mey..Nature and flavor are sweet, and are flat.GUIXIN, lung meridian.But merit hidroschesis.
Folium Dalbergiae Mimosoidis is the leaf of leguminous plant trunk rattan Dalbergia mimosoides Franch.GUIXIN; Spleen channel.But merit heat-clearing and toxic substances removing.
Gumshiraz is rosaceous plant peach Prunus persica (L.) Batsch, the resin that flows out on the trunk.Nature and flavor are bitter, flat.Merit can be invigorated blood circulation, and QI invigorating is quenched the thirst.
Ramulus Cinnamomi is the dry twig of canella Cortex Cinnamomi Cinnamomum cassia Presl.Nature and flavor are hot, sweet, temperature.GUIXIN, lung, urinary bladder channel.But merit diaphoresis expelling pathogenic factors from muscles, promoting the flow of QI-blood by warming the meridian, supporing yang activating QI, the flat gas that spins.
Composition principle: the suppository of Chinese traditional treatment pruritus vulvae, outer lotion are many, but be mostly for Women of Childbearing Age, contain Radix Sophorae Flavescentis, Fructus Cnidii, the Fructus Kochiae, Rhizoma Smilacis Glabrae etc. in the prescription except the medicine of noxious dampness more, and mainly being the mucosa attenuation, the cause of pudendum squamous hyperplasia causes, the medicine external of above dispelling the damp pathogen with drugs of bitter in taste and cold in nature, then irritates nucous membrane more causes aggravation.The object of the invention is to avoid using the dispelling the damp pathogen with drugs of bitter in taste and cold in nature medicine, and reduce from estrogen level, the vaginal wall atrophy, this pathological change angle of mucosa attenuation is started with, and reaches the purpose of " treatment of disease must aim at its pathogenesis ".
Compared with prior art, the present invention has following characteristics:
1, prescription is unique, avoids using the dispelling the damp pathogen with drugs of bitter in taste and cold in nature antipruritic agent: get Cortex erythrinae in the side, go back bobbin and be monarch, Cortex erythrinae dosage of record is in " China's book on Chinese herbal medicine ": " taking orally: fry in shallow oil soup, 6-12g "; The inventor experimental results show that (10 ~ 30g) can recover by specific promotion vaginal wall mucosa middle heavy dose of Cortex erythrinae, and go back bobbin the similar plants estrogen action is arranged, but this act as two-ways regulation, can not produce the low differentiation of the excessive stimulation reproductive system of estrogen cell;
2, characteristic of the present invention also is balance and restriction: record Cortex erythrinae in 1. " must joining book on Chinese herbal medicine ": " insufficiency of blood heated person forbidding ", but the gerontal patient is often with the resembling of deficiency of YIN-blood, and use Cortex erythrinae this moment then has its hematozemia of fearing and causes the yin asthenia generating intrinsic heat appearance; So add Herba Crotalariae Ferrugineae and go back bobbin tonify deficiency training base, can prevent that Cortex erythrinae from consuming cloudy blood and liver-wind stirring up internally, and the Herba Crotalariae Ferrugineae bitter in the mouth is flat, reinforcement and elimination in combination utilizes its cold heated that prevents, in blood system entire merit is arranged out, prevent the Cortex erythrinae moving blood of wandering away, also can not affect Cortex erythrinae simultaneously and work orderly effect; 2. the use of Ramulus Cinnamomi is among the we: a promoting the flow of QI-blood by warming the meridian, and supporing yang activating QI, two Yin Yang balancings are with the bitter cold of balance we invasion by pathogenic cold medicine of a cold nature thing; The application characteristic of Ramulus Cinnamomi is in the prescription of the present invention: measure that larger (" consumption in the Chinese pharmacopoeia is 3 ~ 9g), so too disperse for preventing, gets again Radix Ephedrae convergence assistant system;
3, the supplementary drug thing is fewer but better: get the Flos Magnoliae Amoenae assistant in the side and help Herba Crotalariae Ferrugineae, heat conduction is descending; The Radix Apioris Fortunei heat-clearing and toxic substances removing; The Herba Taxilli assistant helps goes back the bobbin vital base and primordial QI consolidating; Gumshiraz is invigorated blood circulation, and helps medicine to stay in mucomembranous surface, promotes to absorb;
4, inventor's clinical research finds that Fructus Hordei Germinatus (parched to brown), the external of Massa Medicata Fermentata (parched to brown) decoct can promote the local mucous membrane blood circulation;
5, Folium Dalbergiae Mimosoidis is the supplementary drug thing, in " China book on Chinese herbal medicine " record consumption be: " for oral administration: as to fry in shallow oil soup, 9 ~ 15g ", inventor's experimental study are found, get low dose of Folium Dalbergiae Mimosoidis decocting liquid and can improve the vaginal mucosa cytoactive that exsomatizes;
6, the thing homogeneous medicine multiple-effect of getting it filled in the side helps to reduce medicament categories and consumption, does not increase local excitation;
7, medicine material consumption of the present invention is groped to sum up to draw through the inventor in a large number, and each raw material consumption is for all to have preferably curative effect in the following weight parts scope.
The specific embodiment
Below in conjunction with practical situation, the specific embodiment of the present invention is elaborated.
Embodiment 1, the crude drug weight proportion: Cortex erythrinae 20g, Herba Crotalariae Ferrugineae 10g, go back bobbin 6g, Flos Magnoliae Amoenae 10g, Herba Taxilli 6g, Radix Apioris Fortunei 10g, Fructus Hordei Germinatus (parched to brown) 10g, Massa Medicata Fermentata (parched to brown) 10g, Radix Ephedrae 10g, Folium Dalbergiae Mimosoidis 2g, gumshiraz 6g, Ramulus Cinnamomi 20g.
The preparation method of embodiment 1 is: with Cortex erythrinae, Herba Crotalariae Ferrugineae, go back bobbin, Flos Magnoliae Amoenae, Herba Taxilli, Radix Apioris Fortunei, Fructus Hordei Germinatus (parched to brown), Massa Medicata Fermentata (parched to brown), Radix Ephedrae, Folium Dalbergiae Mimosoidis, gumshiraz, Ramulus Cinnamomi mixing and water adding and decoct, get filtrate after 30 minutes, medicinal residues add water continuation decoction and get filtrate after 20 minutes, twice filtrate merges washout, once a day.
Embodiment 2, the crude drug weight proportion: 10 parts of Cortex erythrinaes, 6 parts of Herba Crotalariae Ferrugineaes, go back 3 parts in bobbin, 6 parts of Flos Magnoliae Amoenae, 6 parts of 3 parts of, Radix Apioris Fortunei of Herba Taxilli, 6 parts of Fructus Hordei Germinatus (parched to brown)s, 6 parts of Massa Medicata Fermentata (parched to brown), 6 parts of Radix Ephedraes, 1 part of Folium Dalbergiae Mimosoidis, 3 parts of gumshiraz, 10 parts of Ramulus Cinnamomi.
Embodiment 3, the crude drug weight proportion: 20 parts of Cortex erythrinaes, 10 parts of Herba Crotalariae Ferrugineaes, go back 6 parts in bobbin, 10 parts of Flos Magnoliae Amoenae, 10 parts of 6 parts of, Radix Apioris Fortunei of Herba Taxilli, 10 parts of Fructus Hordei Germinatus (parched to brown)s, 10 parts of Massa Medicata Fermentata (parched to brown), 10 parts of Radix Ephedraes, 2 parts of Folium Dalbergiae Mimosoidiss, 6 parts of gumshiraz, 20 parts of Ramulus Cinnamomi.
Embodiment 4, the crude drug weight proportion: 30 parts of Cortex erythrinaes, 12 parts of Herba Crotalariae Ferrugineaes, go back 10 parts in bobbin, 12 parts of Flos Magnoliae Amoenae, 12 parts of 10 parts of, Radix Apioris Fortunei of Herba Taxilli, 12 parts of Fructus Hordei Germinatus (parched to brown)s, 12 parts of Massa Medicata Fermentata (parched to brown), 12 parts of Radix Ephedraes, 5 parts of Folium Dalbergiae Mimosoidiss, 10 parts of gumshiraz, 25 parts of Ramulus Cinnamomi.
The Chinese medicine of embodiment 2 ~ 4 can be prepared from by following method:
(1) volatile oil is extracted in Cortex erythrinae, Radix Apioris Fortunei, the distilling under reduced pressure of Radix Ephedrae coarse powder difference, and mixing for standby use after collecting, the medicinal residues mixing for standby use;
(2) will go back the bobbin decompression and decoct 2 times, each 30min, collecting decoction leaves standstill rear filtration, gets filtrate for later use;
(3) gained medicinal residues in Herba Crotalariae Ferrugineae, Flos Magnoliae Amoenae, Herba Taxilli, Fructus Hordei Germinatus (parched to brown), Massa Medicata Fermentata (parched to brown), Folium Dalbergiae Mimosoidis, gumshiraz, Ramulus Cinnamomi and the step 1 are added 10 times of water yields, decoct with water 2 times, each 1 hour, collecting decoction left standstill rear filtration, gets filtrate for later use;
(4) step 2 gained filtrate and step 3 gained filtrate are merged, concentrating under reduced pressure becomes dry extract, pulverizes to get dry extract;
(5) gained volatile oil in the step 1 is sprayed in the step 4 gained dry extract, mixing is crossed 100 mesh sieves, and packing forms.
Effective combination of said medicine is coordinated mutually, effectively reach the purpose for the treatment of pudendum squamous hyperplasia, and side effect is less.The above results is the clinical data sufficient proof, and interrelated data is as follows.
1 object and method.
1.1 object.
1 data and method.
1.1.1 case is selected: in March, 2011 ~ 2013 are diagnosed as pudendum squamous hyperplasia 48 examples, 42 years old～69 years old age year April.
1.1.2 diagnostic criteria: with reference to " obstetrics and gynecology " (the 5th edition), all cases is all clarified a diagnosis according to symptom and sign, gynecologial examination.Get rid of trichomonal vaginitis, monilial vaginitis, urine is cultivated negative.
1.1.3 grouping: be divided into washout group and powder group, every group of 24 examples.Compare in age, the state of an illness, the course of disease before two groups of patient treatments, and the difference not statistically significant (P〉0.05), have comparability.
1.2 method.
1.2.1 Therapeutic Method: the washout group is with gained decoct washout in the embodiment of the invention 1,1 time/d.The powder group is blown deposited with gained powder pudendum and intravaginal in the embodiment of the invention 3,1 time/d.28 days is a course for the treatment of.
1.2.2 observation index: conventional inquiry medical history before and after the medication, and according to vaginal health point system (VHS) scoring, determine the doing well,improving situation.
1.2.3 criterion of therapeutical effect: with reference to " obstetrics and gynecology ", recovery from illness: clinical symptoms, sign disappear; Produce effects: clinical symptoms, sign turn for the better by and large; Effectively: clinical symptoms, sign alleviate; Invalid: clinical symptoms, sign are unchanged.
1.2.4 statistical analysis: SPSS 13.0 carries out statistical analysis.Vaginal health scoring single index adopts nonparametric statistics.Measurement data is checked with t, enumeration data χ
2Check.
2 results.
2.1 vaginal symptoms is improved situation: all case pruritus of vagina, dyspareunia symptom all begin to obtain improvement in various degree behind the medication 5d.Gynecologial examination vaginal wall elasticity increases, and fold is deepened, and the surface is pale, flushing and bleeding are clearly better.According to the vaginal health standards of grading, the vaginal health scoring is the summation of elasticity, wettability, pH, mucosa, 5 project score values of secretions.Scoring is 8.52 ± 1.32 before the washout group patient medication, and the scoring average is 13.23 ± 1.63 behind the medication 28d.Scoring is 9.14 ± 2.02 before the powder group patient medication, and the scoring average is 17.72 ± 2.62 behind the medication 28d.Relatively, (P＜0.05) is all obviously increased in the vaginal health scoring behind two groups of patient treatments before and after the medication.
2.2 two groups of Comprehensive Clinical curative effects relatively: behind the medication 28d, the cure rate of washout group, obvious effective rate, effective percentage, inefficiency are respectively 58.33%, 33.33%, 8.33%, 0.00%; The cure rate of powder group, obvious effective rate, effective percentage, inefficiency are respectively 62.50%, 25.00%, 12.50%, 0.00%.
2.3 adverse reaction rate: obvious adverse reaction does not all appear in two groups of patients.
3. conclusion.
This result of study shows that washout group of the present invention and powder group treatment pudendum squamous hyperplasia total effective rate are 100%, has that untoward reaction is light, the higher advantage of safety.
Claims (2)
1. pharmaceutical composition for the treatment of the pudendum squamous hyperplasia is characterized in that being prepared from by the crude drug of following weight proportion: 10 ~ 30 parts of Cortex erythrinaes, 6 ~ 12 parts of Herba Crotalariae Ferrugineaes, go back 3 ~ 10 parts in bobbin, 6 ~ 12 parts of Flos Magnoliae Amoenae, 3 ~ 10 parts of Herba Taxillis, 6 ~ 12 parts of Radix Apioris Fortunei, 6 ~ 12 parts of Fructus Hordei Germinatus (parched to brown)s, 6 ~ 12 parts of Massa Medicata Fermentata (parched to brown), 6 ~ 12 parts of Radix Ephedraes, 1 ~ 5 part of Folium Dalbergiae Mimosoidis, 3 ~ 10 parts of gumshiraz, 10 ~ 25 parts of Ramulus Cinnamomi.
2. a kind of pharmaceutical composition for the treatment of the pudendum squamous hyperplasia according to claim 1 is characterized in that being prepared from by the crude drug of following weight proportion: 20 parts of Cortex erythrinaes, 10 parts of Herba Crotalariae Ferrugineaes, go back 6 parts in bobbin, 10 parts of Flos Magnoliae Amoenae, 10 parts of 6 parts of, Radix Apioris Fortunei of Herba Taxilli, 10 parts of Fructus Hordei Germinatus (parched to brown)s, 10 parts of Massa Medicata Fermentata (parched to brown), 10 parts of Radix Ephedraes, 2 parts of Folium Dalbergiae Mimosoidiss, 6 parts of gumshiraz, 20 parts of Ramulus Cinnamomi.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510381409.7A CN105012793A (en) | 2013-07-01 | 2013-07-01 | Preparation method of skin-wash liquid for treating vulvar cell hyperplasia |
| CN201310270636.3A CN103356932B (en) | 2013-07-01 | 2013-07-01 | A pharmaceutical composition for treating vulvar squamous epithelial cell hyperplasia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310270636.3A CN103356932B (en) | 2013-07-01 | 2013-07-01 | A pharmaceutical composition for treating vulvar squamous epithelial cell hyperplasia |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510381409.7A Division CN105012793A (en) | 2013-07-01 | 2013-07-01 | Preparation method of skin-wash liquid for treating vulvar cell hyperplasia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103356932A true CN103356932A (en) | 2013-10-23 |
| CN103356932B CN103356932B (en) | 2015-08-26 |
Family
ID=49359734
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510381409.7A Pending CN105012793A (en) | 2013-07-01 | 2013-07-01 | Preparation method of skin-wash liquid for treating vulvar cell hyperplasia |
| CN201310270636.3A Expired - Fee Related CN103356932B (en) | 2013-07-01 | 2013-07-01 | A pharmaceutical composition for treating vulvar squamous epithelial cell hyperplasia |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510381409.7A Pending CN105012793A (en) | 2013-07-01 | 2013-07-01 | Preparation method of skin-wash liquid for treating vulvar cell hyperplasia |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN105012793A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103316269A (en) * | 2013-07-01 | 2013-09-25 | 付海霞 | Medicine composition for treating primary enuresis |
| CN103316258A (en) * | 2013-07-01 | 2013-09-25 | 王莉莉 | Medicine composition for treating infantile vaginitis |
| CN103316270A (en) * | 2013-07-01 | 2013-09-25 | 丁霄雁 | Preparation method of powder of medicine for treating postnatal perineum mucosal lesion |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1943665A (en) * | 2005-10-08 | 2007-04-11 | 刘国飞 | A Chinese traditional medicinal composition and its preparation method |
-
2013
- 2013-07-01 CN CN201510381409.7A patent/CN105012793A/en active Pending
- 2013-07-01 CN CN201310270636.3A patent/CN103356932B/en not_active Expired - Fee Related
Non-Patent Citations (1)
| Title |
|---|
| 韩延华等: "中西医结合治疗外阴鳞状上皮细胞增生、硬化性苔癣的临床观察", 《中华中医药杂志》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103316269A (en) * | 2013-07-01 | 2013-09-25 | 付海霞 | Medicine composition for treating primary enuresis |
| CN103316258A (en) * | 2013-07-01 | 2013-09-25 | 王莉莉 | Medicine composition for treating infantile vaginitis |
| CN103316270A (en) * | 2013-07-01 | 2013-09-25 | 丁霄雁 | Preparation method of powder of medicine for treating postnatal perineum mucosal lesion |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103356932B (en) | 2015-08-26 |
| CN105012793A (en) | 2015-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103520572A (en) | Traditional Chinese composition used for treating atopic dermatitis as well as preparation method of composition | |
| CN103055285B (en) | Traditional Chinese medicine for treating forepart hepetocirrhosis and preparation method thereof | |
| CN103341092A (en) | Preparation method of powder for treating atrophic vaginitis | |
| CN103356932A (en) | A pharmaceutical composition for treating vulvar squamous epithelial cell hyperplasia | |
| CN103285284B (en) | Medical composition for treating senile vaginitis | |
| CN103301353B (en) | Pharmaceutical composition for treating atrophic vaginitis | |
| CN103611021B (en) | Be used for the treatment of medicine of Vesica sus domestica inflammation and preparation method thereof | |
| CN103301373B (en) | Pharmaceutical composition for treating postpartum perineal mucosal lesions | |
| CN104257778A (en) | Traditional Chinese medicine for treating rheumatic arthritis | |
| CN103341094B (en) | Preparation method of powder for treating vulva squamous epithelial cell hyperplasia | |
| CN103285300B (en) | Medicinal composition for treating stress incontinence | |
| CN105749167A (en) | Traditional Chinese medicine composition for treating amenorrhea | |
| CN103301374B (en) | Pharmaceutical composition for treating postpartum non-specificity vaginitis | |
| CN104758733A (en) | External lotion for treating senile vaginitis | |
| CN103316270B (en) | Preparation method of powder of medicine for treating postnatal perineum mucosal lesion | |
| CN103330896B (en) | Preparation method of powder for treating postpartum nonspecific vaginitis | |
| CN119857125B (en) | A Chinese medicine composition for improving male sexual function, and its preparation method and use | |
| CN103705629B (en) | A kind of Chinese medicine composition for the treatment of pruritus | |
| CN109091570A (en) | A kind of Chinese medicine for treating chorionitis | |
| CN103316258B (en) | Medicine composition for treating infantile vaginitis | |
| CN105998559A (en) | Traditional Chinese medicine composition for treating Parkinson's disease | |
| CN105727237A (en) | Folium artemisiae argyi-containing pharmaceutical composition for treating amenorrhea | |
| CN104922595A (en) | Traditional Chinese medicinal preparation for herpes zoster and preparation method thereof | |
| CN104758539A (en) | Traditional Chinese medicine composition for treating debilitation | |
| CN103301378B (en) | Pharmaceutical composition for treating nocturia of children |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: CHEN YU Free format text: FORMER OWNER: ZHANG SHIYE Effective date: 20150722 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent of invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Chen Yu Inventor before: Zhang Shiye |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: ZHANG SHIYE TO: CHEN YU |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20150722 Address after: 276826 Rizhao People's Hospital, 126 Tai'an Road, Shandong, Rizhao City, China Applicant after: Chen Yu Address before: 276826 Rizhao City traditional Chinese medicine hospital, 35 Hai Lu, Shandong, Rizhao City Applicant before: Zhang Shiye |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150826 Termination date: 20160701 |